No Data
No Data
RAPT Therapeutics Reprices Underwater Employee Stock Options
Here's Why We're A Bit Worried About RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation
RAPT Therapeutics Reports Improved Q3 2024 Results
Stifel Maintains RAPT Therapeutics(RAPT.US) With Hold Rating, Maintains Target Price $2
Piper Sandler Maintains RAPT Therapeutics(RAPT.US) With Hold Rating, Cuts Target Price to $2
Stifel Nicolaus Downgrades RAPT Therapeutics to Hold From Buy, Cuts Price Target to $2 From $7
No Data
No Data